Skip to main
PAVM

PAVmed (PAVM) Stock Forecast & Price Target

PAVmed (PAVM) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PAVmed Inc. has demonstrated a consistent upward trajectory in processing EsoGuard tests, with an increase from 2,756 tests in Q2 to 2,841 tests in Q3, highlighting a positive trend in utilization of its diagnostic product offerings. Additionally, the company's valuation appears favorable, with an NPV analysis indicating significant upside potential when balancing the associated risks of its business model. The ongoing commercialization of PAVmed's products, coupled with expectations for substantial growth in the coming years, further supports optimism for the company's financial future.

Bears say

PAVmed Inc has reported a pro forma net loss of $0.8 million, resulting in an earnings per share (EPS) of $(0.05), which is better than previous estimates but reflects ongoing financial challenges. Additionally, the company experienced a decline in EsoGuard test processes, with only 2,756 tests conducted in Q2 compared to higher volumes in preceding quarters, indicating reduced demand for its diagnostic product. Furthermore, PAVmed's Lucid business remains in the early stages of commercialization, and the firm faces multiple risks, including liquidity concerns, regulatory hurdles, and competition, which contribute to a negative outlook on its financial health and future growth potential.

PAVmed (PAVM) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PAVmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PAVmed (PAVM) Forecast

Analysts have given PAVmed (PAVM) a Strong Buy based on their latest research and market trends.

According to 1 analysts, PAVmed (PAVM) has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PAVmed (PAVM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.